Cargando…

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Detalles Bibliográficos
Autores principales:	Klodzinskiy, A., Turgunova, L., Butyugina, M., Kakhanova, M., Pivovarova, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429341/ http://dx.doi.org/10.1097/01.HS9.0000850328.31449.82

Ejemplares similares

PB2584: EXPLOSIVE GROWTH ANTIMICROBIAL RESISTANCE IN CENTRAL KAZAKHSTAN IN ONCOHEMATOLOGICAL PATIENTS IN POST COVID PERIOD
por: Lyssenko, Angelina, et al.
Publicado: (2023)

PB1957: PROGNOSTIC SIGNIFICANCE OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGHV-U IN THE ERA OF NOVEL AGNETS; REAL-LİFE DATA
por: Arikan, Fatma, et al.
Publicado: (2023)

PB1868: EXPERIENCE IN THE TREATMENT OF HAIRY CELL LEUKEMIA IN KAZAKHSTAN.
por: Kemelbekov, N., et al.
Publicado: (2022)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB1855: LACK OF MUTATIONS IN TNFRSF13B (TACI) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Giannakoulas, N., et al.
Publicado: (2022)

PB1870: COVID - 19 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: HOSPITAL MORALITY PREDICTORS
por: Kochneva, O., et al.
Publicado: (2022)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jorge #, J., et al.
Publicado: (2022)

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB1920: TARGETING THE TUMOR MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING LEUKOTRIENE INHIBITORS
por: Sadeghi, Laia, et al.
Publicado: (2023)

PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Paziewska, Magdalena, et al.
Publicado: (2023)

PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Karan-Đurašević, Teodora, et al.
Publicado: (2023)

PB1871: PROGNOSTIC SIGNIFICANCE OF THE NOTCH1 GENE MUTATION AND OTHER LABORATORY FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Krauchanka, D., et al.
Publicado: (2022)

PB1888: EFFICACY OF FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A BAYESIANNETWORK META-ANALYSIS.
por: Chanan-Khan, A., et al.
Publicado: (2022)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

PB1946: NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV-INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Shang, Chunyu, et al.
Publicado: (2023)

PB1951: PROGNOSTIC SIGNIFICANCE OF CLINICAL INDICATORS RELATED TO AMINO ACID METABOLISM IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Liu, Ming, et al.
Publicado: (2023)

PB1914: UNPRECEDENTED ACCUMULATION OF 5-HYDROXYMETHYLURACIL IN CHRONIC LYMPHOCYTIC LEUKEMIA –POTENTIAL SOURCES AND CLINICAL IMPLICATIONS
por: Gackowski, Daniel, et al.
Publicado: (2023)

PB1875: TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY
por: Miled, W., et al.
Publicado: (2022)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

PB1941: MIND-BODY INTERVENTION PROLONGS LYMPHOCYTE DOUBLING TIME AND TREATMENT-FREE SURVIVAL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Shapira, Shirley, et al.
Publicado: (2023)

PB1887: NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Chanan-Khan, A., et al.
Publicado: (2022)

PB1857: NRF2 MODULATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A POSSIBLE NEW THERAPEUTIC APPROACH
por: Carda #, J. P., et al.
Publicado: (2022)

PB1956: ANALYSIS OF CLINICAL COURSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMPLEX KARYOTYPE – SINGLE CENTRE EXPERIENCE
por: Sarac, Sofija, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

PB1744: THE RATIO OF ABSOLUTE LYMPHOCYTE COUNT AT INTERIM OF THERAPY TO ABSOLUTE LYMPHOCYTE COUNT AT DIAGNOSIS PREDICTS SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA
por: Faiza, Talbi, et al.
Publicado: (2023)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB1882: BONE MARROW LYMPHOCYTES AND SUBPOPULATION: A NOVEL PROGNOSTIC INDICATOR IN ACUTE MYELOID LEUKEMIA
por: Ibrahim, Nahla
Publicado: (2023)

PB2334: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB1931: LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL-IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gao, Rui, et al.
Publicado: (2023)

PB1982: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF CHRONIC MYELOID LEUKEMIA: EXPERIENCE OF FATTOUMA BOURGUIBA HOSPITAL OF MONASTIR
por: Lakhel, Sana, et al.
Publicado: (2023)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR OTHER NON-HODGKIN LYMPHOMA
por: Kahl, B., et al.
Publicado: (2022)

PB1831: THE BALANCE BETWEEN STAT3 ISOFORMS AS ESSENTIAL FEATURE IN ACUTE MYELOID LEUKEMIA
por: Weiss, Stefanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pkklv4ndvl62isl6edm38vafds